CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
No Chemotherapy in Intermediate-risk HR + HER2- Early Breast Cancer Treated with Ribociclib (NoLEEta)
We are pleased to inform you that the Canadian Cancer Trials Group (CCTG) is organizing our next Clinical Research Associate (CRA) Lunch and Learn training program, to be held on Wednesday, May 13th, 2026, at 12 pm ET on the topic: NCTN Clinical Trial Support Unit (CTSU) OPEN System and upcoming changes
Thank you to everyone who attended the 2026 CCTG Annual Spring meeting! With it now behind us, please ensure you keep the following deadlines in mind:
CME submission deadline May 29th
The Annual Spring Meeting is an accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University Office of CPD. You may claim a maximum of 25.5 hours (Credits are automatically calculated).
Congratulations to Lynn Dwernychuk for being honoured with the CCTG Award for Excellence in Clinical Trials Conduct, presented to her last weekend at the Annual Spring Meeting of Participants. Lynn was recognized by her peers as an individual who exemplifies excellence in clinical trial operations and compliance. She serves as the Director of Clinical Research at the Saskatchewan Cancer Agency and holds an Adjunct Professorship with the College of Graduate Studies and Research at the University of Saskatchewan.
The CCTG Pharmacy Network is actively seeking pharmacy representation for the following:
CCTG is delighted to recognize the early career of Dr. Jelena Lukovic who was presented with the CCTG Dr. Ralph Meyer Phase III Young Investigator Award this past weekend at the Spring Meeting of Participants in Toronto. This award is given to an outstanding young investigator who is working on a CCTG Phase III clinical trial.She is the Canadian PI for the international NEEDS trial evaluating definitive chemoradiotherapy for squamous cell esophageal cancer.
